ICONIC CLASS
agency: Concentric Pharma Advertising
brand: Betaseron
client: Bayer
photo from left: Michael Rowe, executive director of marketing, therapeutics business unit, Bayer • Ken Begasse, Jr., chief operating officer • Michael Sanzen, chief creative officer • Aimee Eastwood, associate creative director, copy • (Not pictured: Sayan Ray, creative director, art)
How do you revive a brand that hasn't captured market share since 1995? If you're Concentric, you blow it up through key insights into the latest clinical data and create what amounts to an explosive campaign.
Of course, it helps that clinical opinion has come to support early-stage treatment of multiple sclerosis patients with high-dose, high-frequency products—a key selling point of Betaseron. And Concentric knew what Bayer needed to do to capitalize on the changing treatment trends.
"Our challenge was to take these new studies and all this great data and make the physician take notice that the drug is now relevant," explains Concentric's Ken Begasse, Jr.
Concentric wanted to remind physicians that MS does damage from the start and make them notice Betaseron's efficacy in early-stage MS.
This led Concentric to create an iconic image of an orange axon (nerve fiber) lit up like a brightly burning fuse. Against the dark-blue background, the axon fuse is a visual trigger of the damage—and pain—MS patient experience and reminds physicians about the importance of immediate treatment. With the tagline "Not a Moment to Lose," Bayer created a quick, effective catchphrase. Docs recalled the efficacy message, which reps trained up on using the interactive video game sales tool called Rep Race.
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.